Stemmax Research and Therapeutics Private Limited
About Stemmax Research and Therapeutics Private Limited
Data last updated:
Stemmax Research and Therapeutics Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 07 February 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U33309DL2017PTC312451. Its GSTIN is 07AAYCS1087L1ZI (Delhi).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Prabhu Chandra Mishra and Umesh Chandra Mishra.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 69 Plot No. 35 Kallol Apartment I.P. Extn., New Delhi, Delhi, India – 110092.
As per the financials filed for FY 2025, the company reported a revenue of ₹2.21 Cr, a growth of 39% compared to the previous year. For the same year it recorded a net profit of ₹6.17 Lakh (net margin 2.8%) and EBITDA of ₹11.42 Lakh (EBITDA margin 5.2%). Revenue has grown at a compounded annual rate (CAGR) of 64% over three years and 46% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Stemmax Research and Therapeutics Private Limited's registered office is in New Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered Address69 Plot No. 35 Kallol Apartment I.P. Extn., New Delhi, Delhi, India – 110092
- IndustryPharma, Pharma Contract R&D
To see the full contact details of Stemmax Research and Therapeutics Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Stemmax Research and Therapeutics is professional, scientific and technical. In detail, this covers other professional, scientific and technical activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Stemmax Research and Therapeutics Private Limited, buy the company report.
Financials of Stemmax Research and Therapeutics Private Limited
FY 2025 filings availableStemmax Research and Therapeutics Private Limited reported revenue of ₹2.21 Cr (up 39% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 46% over five years, including 39% growth in the latest year. EBITDA rose 22% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹11.42 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹6.17 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 5.2% | ||||
| Net Profit Margin | 2.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Stemmax Research and Therapeutics Private Limited, buy the company report.
Board of directors of Stemmax Research and Therapeutics Private Limited
Stemmax Research and Therapeutics has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Prabhu Chandra Mishra | Director | 07 Feb 2017 | 9 Years 8 Months | Current |
| Umesh Chandra Mishra | Director | 07 Feb 2017 | 9 Years 8 Months | Current |
Auditor
Stemmax Research and Therapeutics Private Limited is audited by JAIN SUBHASH CHAND & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| JAIN SUBHASH CHAND & CO. | FY 2023 | 006490C |
Shareholding
The shareholding of Stemmax Research and Therapeutics Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Stemmax Research and Therapeutics Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Stemmax Research and Therapeutics Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Stemmax Research and Therapeutics Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Stemmax Research and Therapeutics has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAYCS1087L1ZI | Delhi | Active | 08 Jan 2018 |
To see the full GST registrations and return filing status of Stemmax Research and Therapeutics Private Limited, buy the company report.
Recent activity
Stemmax Research and Therapeutics Private Limited has 2 board changes on record since 2017: 2 appointments. The latest: Prabhu Chandra Mishra was appointed as Director on 07 Feb 2017.
Frequently asked questions
Stemmax Research and Therapeutics is an active private limited company based in New Delhi, Delhi, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 07 February 2017 (9+ years old) and is registered under CIN U33309DL2017PTC312451.
Stemmax Research and Therapeutics has 2 current directors:
- Prabhu Chandra Mishra - Director
- Umesh Chandra Mishra - Director
The latest financial statements of Stemmax Research and Therapeutics on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2017 are in the company report.
The GSTIN of Stemmax Research and Therapeutics is 07AAYCS1087L1ZI, registered in Delhi.
The CIN (Corporate Identification Number) of Stemmax Research and Therapeutics is U33309DL2017PTC312451. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Stemmax Research and Therapeutics was incorporated on 07 February 2017, making it 9+ years old. It is registered with the Registrar of Companies, Delhi.
Prabhu Chandra Mishra was appointed as Director on 07 Feb 2017. Umesh Chandra Mishra was appointed as Director on 07 Feb 2017.
The registered office of Stemmax Research and Therapeutics is at 69 Plot No. 35 Kallol Apartment I.P. Extn., New Delhi, Delhi, India – 110092.
Stemmax Research and Therapeutics operates in the pharma industry, in the pharma contract r and d segment.
The compliance status of Stemmax Research and Therapeutics is compliant as of 24 July 2026. The company is actively filing with the Registrar of Companies.